【摘要】 目的:探讨微生态制剂联合兰索拉唑、克拉霉素片、阿莫西林胶囊在幽门螺杆菌感染治疗中的疗效及安全性。方法:将118例慢性胃炎或消化性溃疡且经快速尿素酶试验、病理切片染色镜检、13C-尿素酶呼气试验检测幽门螺杆菌任何两项阳性患者随机分为联合治疗组60例,常规三联方根除治疗(兰索拉唑+克拉霉素+阿莫西林胶囊)加0.35 g双歧杆菌片0.7 g 2次/d,口服,与抗菌药物间隔2 h服用,疗程14 d。对照组58例,常规三联方根除治疗(兰索拉唑+克拉霉素+阿莫西林胶囊)不使用双歧杆菌,疗程14 d。治疗结束4周后复查13C-尿素酶呼气试验。比较两组根除率及不良反应发生率。结果:联合治疗组根除率80%,对照组根除率77.5%,两组间差异无统计学意义(P>0.05),但是联合治疗组不良反应发生率6.7%与对照组不良反应发生率22.4%比较差异具有统计学意义(P<0.05)。结论:常规三联疗法结合双歧杆菌片在幽门螺杆菌感染治疗中不良作用少,患者依从性较好,值得临床推广和应用。更多还原

【Abstract】 Objective: To study the efficacy and safety of triple therapy(lansoprazole, clarithromycin tablets, and amoxicillin capsules)with probiotics in the treatment of helicobacter pylori infection. Methods:118 cases of chronic gastritis or peptic ulcer with any two positive results of rapid urease test, pathological staining,13C- urease expiratory test were randomly divided into two groups: 60 cases of combined treatment group, lansoprazole clarithromycin and Amoxicillin capsules with 0.35 g of bifidobacterium 0.7 g Po, bid, and 2 h interval taking antibiotics, course 14 d, 58 cases of the control group, lansoprazole clarithromycin and Amoxicillin capsules without Bifidobacterium, course 14 d. Repeat13C- urea breath test after 4 weeks. Compare the eradication rate and adverse reaction rate of two groups. Results: the eradication rate of treatment group was 80%; the control group the eradication rate was 77.5%, there was no significant difference between the two groups(P>0.05), but the adverse reaction incidence were statistically significant different(P <0.05) between treatment group 6.7% and control group 22.4%. Conclusion: Triple therapy with bifidobacterium tablets in the treatment of Hp infection which has less side effect, is worthy of clinical application.更多还原